CD33 and neoplasm: In the triple-positive tumor cells (EpCAM+FOLR1+CD24+), the merging of the two datasets resulted in the expression of additional markers traditionally not examined in tumor cells: CD33, CD303, and CD95, which are involved in cell signaling, antigen capture, and immune homeostasis and cell apoptosis, respectively (Addendum 1).